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Abstract
Elimination of cancer cells by early apoptosis is preferred over other forms of cell growth inhibition. Apoptosis directly leads to tumor
regression and reduces risks of selecting more aggressive and/or drug-resistant phenotypes that are often responsible for tumor regrowth and
treatment failure. Although DNA damage by anticancer drugs is commonly recognized as an apoptotic stimulus, there is enormous variability
in the magnitude and timing of such effects. Especially potent and rapid apoptosis seems to be a hallmark of various alkylating anticancer
drugs that are regarded as DNA-reactive agents but are observed to react mainly with cellular proteins. Our studies with such dual-action
drugs (irofulven, oxaliplatin) suggest that not only DNA damage, but also protein damage, contributes to apoptosis induction. DNA damage
is well known to initiate death-signaling pathways leading to mitochondrial dysfunction. Protein damage, in turn, can distort cell redox
homeostasis, which facilitates apoptosis execution. Such dual effects can be particularly lethal to tumor cells, which tend to function under
pro-oxidative conditions. In contrast to tumor cells that are highly susceptible, normal cells show marginal apoptotic responses to the dual
action drugs. This protection of normal cells might reflect their greater ability to buffer pro-oxidative changes and quickly restore redox
homeostasis, despite substantial drug uptake and macromolecular binding. Importantly, by targeting the death process at multiple points,
DNA- and protein-damaging drugs can be less vulnerable to various bypass mechanisms possible with single targets. The reviewed studies
provide a proof of concept that differential apoptosis targeting in cancer versus normal cells can be a basis for tumor selectivity of anticancer
drugs. D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction: the need for apoptosis in anticancer
strategies
Whereas the ultimate goal of all anticancer strategies is
to eradicate tumor cells, early apoptosis is by far the phar-
macologically preferred form of cell growth inhibition. A
rapid death of cancer cells is not only needed to achieve
tumor regression but also to reduce risks of selecting
more aggressive and/or drug-resistant phenotypes that are
often responsible for tumor regrowth and treatment failure
(Fig. 1). Slowly growing but viable tumor cells, recovering
from non-apoptotic damage, were proposed to be an
overlooked factor in the therapeutic failure of various
cancer treatments [1]. Unless such cells are physically
eliminated, there is a remaining danger of clonal selection
and tumor recurrence. Initiation of apoptosis irrevocably
eliminates this threat since apoptotic cells cannot be
clonogenic.
Conversely, dysregulation of normal apoptosis pathways
extends the cell life span and can contribute to tumor
expansion, even if the cell division rate remains normal
[2]. Hence, targeting apoptosis is particularly relevant to
those forms of cancer that have a significantly reduced rate
of cell death and are relatively slowly proliferating tumors.
For instance, slowly dividing prostate cancer cells are very
difficult to eradicate with current anticancer drugs, which
target rapidly proliferating cells [3]. Being a physiological
process, apoptosis is associated with fewer side effects
than non-apoptotic modes of cell death. Various antican-
cer drugs induce apoptosis but there is enormous varia-
bility in the magnitude and timing of such effects. Recent
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years have brought an increased understanding of the
complexity of cellular responses to drug interactions with
a variety of cellular targets that ultimately result in cell
death [4,5]. This review discusses the potential for selec-
tive targeting of apoptosis in cancer cells focusing on
novel anticancer drugs that react with cellular DNA and
proteins.
2. Central role of redox imbalance in apoptosis
Whereas various insults can initiate apoptosis (for a
recent review, see Ref. [6]), a consistent picture that emerges
from studies in various laboratories points to the pivotal role
of redox homeostasis in apoptotic process. Oxidative stress
and reactive oxygen species can be either the initiating
stimulus or mediator of apoptosis [7,8]. Factors that regulate
the levels and responses to oxidative stress [9–11] are
believed to play a decisive role in determining the ‘‘point
of no return’’ in cell death [12–14]. In that context, the
mitochondria are now well established as critical for pro-
cessing and integrating pro-apoptotic signals. Diverse apop-
totic stimuli can cause mitochondrial dysfunction leading to
pro-oxidative changes in redox homeostasis. Pro-oxidants
per se cause the efflux of mitochondrial components, further
increasing the oxidative stress [8,10,15,16].
The cross-talk between cellular signaling and the redox
status of the cell is presently believed to dictate, more than
any other factors, whether or not a cell will undergo
apoptosis [10,11,13]. A balance of pro- and anti-apoptotic
factors allows cells to survive despite various insults for
prolonged times. However, apoptosis seems to proceed like
a chain reaction and relatively small perturbations in the
equilibrium may either rapidly amplify or successfully
attenuate the process. The amplification or attenuation of
pro-apoptotic responses is tightly coupled to the thiol redox
status of the cell, with a critical role of protein sulfhydryls
[10,17,18].
Whereas glutathione system provides redox buffering at
the level of small molecule sulfhydryls, the thioredoxin
(TRX) family of multifunction disulfide reductases is the
key system responsible for maintaining the reduced form of
protein sulfhydryls [17,19–21]. TRX participates directly in
cellular death signaling pathways by inhibiting apoptosis
signal-regulating kinase 1 (ASK 1) and the subsequent ASK
1-dependent apoptosis [18]. TRX also mediates the effects
of redox-sensing transcription factors, which allow the cell
to reprogram its gene expression in response to pro-oxida-
tive insults [11,21,22]. The rapidly inducible increase in
TRX expression can prevent apoptosis [9,16], consistent
with the reports implicating TRX in the resistance of cancer
cells to drug-induced apoptosis [23–26].
Fig. 1. The significance of apoptosis for antitumor drugs. The elimination of affected cells by early, ideally premitotic apoptosis is the most desirable scenario.
Postmitotic apoptosis can eliminate additional cancer cells. However, each mitotic attempt poses a risk that genetic rearrangements may lead to the selection of
cells with a more aggressive and/or resistant phenotype. Viable cells that are not eliminated may not form scorable colonies under typical assay conditions but
may resume growth and lead to tumor recurrence.
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3. Is drug-induced DNA damage sufficient for apoptosis
induction?
3.1. DNA damage as apoptotic stimulus
Lesions in DNA are generally considered as the primary
apoptotic stimulus for DNA-damaging agents. DNA dam-
age elicits complex responses which are mediated by
various intracellular and extracellular factors such as p53,
abl, c-myc, Rb, E2F, growth factors, and which often
involve multiple and redundant pathways [27,28]. If these
responses are not extinguished by anti-apoptotic signals
(such as Bcl-2), Bax and related death proteins decrease
mitochondrial membrane potential (DW) [29–31], which, in
turn, leads to cytochrome c release and oxidative stress
[16,32–36], followed by the activation of cysteine proteases
of the caspase family and subsequent apoptotic DNA
fragmentation [37]. This general route has been implicated
in the action of various DNA-damaging agents [5,38–40]
(Fig. 2). Beyond doubt, DNA damage can be a critical factor
for the action of anticancer drugs. It is important to
recognize, however, that it represents only one facet of the
pleiotropic reactivities of nominally DNA-reactive drugs.
3.2. Protein damage as apoptotic stimulus
The profound ability of various alkylating drugs to bind
cellular proteins seems to be particularly under-appreciated
as a contributing factor in apoptotic responses. The normally
functioning cell maintains reductive conditions. Numerous
proteins require reduced sulfhydryl groups for their proper
function. It is well established that compounds that form
adducts only with proteins, such as diamide, distort the
redox homeostasis of the cell in the pro-oxidative direction
[10,41–46] (Fig. 2). Consequently, thiol-reactive com-
pounds themselves can induce apoptosis without reacting
with cellular DNA [10,42,44,46].
Importantly, the thiol–disulfide balance has also been
implicated in redox-sensitive gene expression, which drives
critical steps in signal transduction [22,47–49]. Drug binding
to sulfhydryl-containing proteins, especially those involved
in redox regulation, may have a profound effect on cellular
responses determining apoptosis progression. If TRX and
related systems can respond in a sufficient and timely manner,
transcriptional reprogramming can increase the redox buffer-
ing capacity of the cell and annihilate the effects of potentially
apoptotic insults. However, extensive protein damage is
likely to compromise the cell capacity for such restorative
responses and precipitate responses that accelerate rather than
slow down cell self-deterioration. Given that tumor cells may
have already a compromised capacity to buffer pro-oxidative
changes, the ‘‘redox factor’’ resulting from drug-induced
protein damage could be of profound importance for both
the efficiency and selectivity of drug-induced apoptosis.
3.3. The puzzle of DNA- and protein-reactive antitumor drugs
Several lines of observations strongly suggest that DNA
damage does not fully account for the pro-apoptotic effects of
at least some nominally DNA-reactive drugs. New clinically
Fig. 2. Model for processing of DNA and protein damage in apoptosis. DNA damage elicits complex death signaling pathways that ultimately lead to
mitochondrial dysfunction. Mitochondria process and integrate pro-apoptotic signals triggered by other apoptotic stimuli, including protein damage and pro-
oxidative changes. Pro-oxidative distortion of redox homeostasis appears to be a common mediator of apoptosis by various stimuli. Whereas the glutathione
(Glu-SH) system can buffer redox changes at the level of small molecules, the thioredoxin (TRX) system is a key component controlling the redox status of the
protein sulfhydryls. Downstream effects can provide positive feedback loops (dotted arrows) resulting in the self-amplifying nature of apoptosis.
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relevant anticancer drugs, irofulven and oxaliplatin, belong
to the category of agents that bind to cellular DNA but mainly
react with cellular proteins. Irofulven (HMAF, hydroxyme-
thylacylfulvene, MGI 114, NSC 683863, Fig. 3) is a semi-
synthetic analog of the sesquiterpene Illudin S [50]. This drug
is currently undergoing a Phase III clinical trial for gemcita-
bine-refractory pancreatic cancer and several Phase II trials
for different tumor types [51–54]. Irofulven binds to cellular
DNA but appears to form only monoadducts [55,56], usually
not considered as lethal lesions. Yet, the drug is a potent
apoptosis inducer [55,57] and produces tumor shrinkage and
curative antitumor effects in several human xenograft models
[58–62]. Not only does irofulven bind to multiple cellular
proteins but also the magnitude of protein adducts (60% of
total covalent adducts) exceeds nearly four-fold the levels of
cellular DNA adducts [56].
Oxaliplatin, a third generation platinum antitumor analog
in which 1,2 diaminocyclohexane ligand substitutes the
amine groups of cisplatin, has demonstrated a broad spec-
trum of activity in a wide range of human tumors in vitro
and in vivo [63] (Fig. 3). Our studies showed that oxali-
platin forms fewer DNA lesions than its parent drug
cisplatin at equimolar concentrations [64,65]. In spite of
reduced DNA damage, oxaliplatin is at least as cytotoxic
and as potent inducer of apoptosis as cisplatin [64]. More-
over, oxaliplatin is clinically superior to cisplatin by being
less toxic and retaining activity against cisplatin-resistant
tumors [63,66,67]. Whereas protein reactivity of oxaliplatin
has not been directly investigated, binding to cellular pro-
teins of platinum drugs is, in general, an order of magnitude
greater than DNA binding (f 75–85 vs. f 10% of total
cellular adducts, respectively, for cisplatin [68,69]). More-
over, the hydrophobic diaminocyclohexane moiety in oxali-
platin may facilitate drug interaction inside hydrophobic
pockets of cellular proteins [65].
3.4. DNA and protein damage as apoptotic stimuli for
irofulven and oxaliplatin?
An intriguing possibility is that functional protein dam-
age (interference with enzymatic, receptor and/or structural
functions) may markedly contribute to apoptosis induction
by DNA- and protein-reactive drugs, such as irofulven and
oxaliplatin. To address this possibility, we compared the
levels of apoptosis induced by these dual-action drugs with
apoptosis by diamide, which binds only proteins, and
apoptosis by bizelesin, a drug that reacts only with DNA
[70] (Fig. 3). The protein damaging agent, diamide, and dual
action drugs, irofulven and oxaliplatin, were found to induce
apoptosis at pharmacologically relevant levels. In contrast,
the purely DNA-damaging drug bizelesin induced only
marginal levels of apoptotic DNA fragmentation at supra-
lethal concentrations. Since bizelesin, diamide, irofulven
and oxaliplatin were all compared at equitoxic levels, our
Fig. 3. Examples of pro-apoptotic DNA- and protein-damaging drugs (irofulven, oxaliplatin and cisplatin). Model single action drugs, diamide and bizelesin,
represent compounds that react only with protein and DNA, respectively.
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results illustrate the situation when protein damage alone
may be sufficient, and DNA damage alone insufficient, for
substantial apoptosis [57,71–73] (Fig. 4).
The effects of irofulven and oxaliplatin suggest that
the most potent apoptosis induction occurs when both
DNA- and protein reactivities are combined. Such a self-
potentiating apoptosis can explain the potent pro-apop-
totic and antiproliferative effects of irofulven and oxali-
platin [55,57,64,65,73]. DNA adducts by these drugs, like
DNA damage, in general, are probably important in initiat-
ing death signaling. However, if DNA damage is accom-
panied by protein damage, apoptotic progression might
accelerate. Although woefully understudied, protein dam-
age is highly likely to contribute as well to the apoptotic
effects of other dual-action drugs. Notably, a recent study
by other authors linked apoptosis induction to protein da-
mage by helenalin [74]. This antitumor agent, like iro-
fulven, is a sesquiterpenoid capable of reacting with protein
sulfhydryls, but possibly does not react with DNA [75].
Importantly, protein damage would push cell metabolism in
the same pro-apoptotic direction as DNA lesions but acting
in a nonoverlapping manner at the redox level, i.e., down-
stream from DNA damage-inducible death signaling. The
idea that protein-damage may actively contribute to apop-
tosis induction by DNA-damaging agents challenges the
common belief that binding of a DNA-reactive drug to
proteins is merely a ‘‘detoxification’’ event. Collectively,
the results with model compounds and known pro-apoptotic
properties of other protein-damaging agents strongly sug-
gest that DNA- and protein-reactive drugs may be partic-
ularly suitable for targeting apoptosis.
4. Preferential apoptosis induction in tumor cells by dual
action drugs
A question of paramount importance for targeting apop-
tosis with dual-action drugs is whether they have the ability
to selectively affect tumor cells. Our recent studies, dis-
cussed below, provide a proof of concept that differential
apoptosis in cancer versus normal cells is feasible and can
be considered as a potential basis for tumor selectivity with
apoptosis targeting strategies.
4.1. Differential apoptotic responses in tumor versus normal
cells
The potent induction of apoptosis is the most prominent
feature of irofulven action in various tumor cell systems,
including several human prostate, colon, breast and leukemia
tumor cell lines [55–57,76,77]. In striking contrast to tumor
cells, normal cells tend to be remarkably resistant to the
induction of apoptosis by irofulven treatment. Marginal or
very low levels of apoptosis, as measured by DNA fragmen-
Fig. 4. Apoptotic potential of single and dual-action drugs [71,73]. Human leukemia CEM cells were treated for 24 h with model drugs damaging only proteins
(diamide), only DNA (bizelesin), and both DNA and protein (irofulven and oxaliplatin). To relate the effectiveness of these agents to the pharmacologically
relevant levels, the abscissa indicates equitoxic concentrations expressed as the multiples of the IC80 values (drug concentrations inhibiting cell growth by
80%). The examples shown are for quantitative DNA fragmentation assay. Analogous pattern of apoptotic potential was found based on changes in cell
morphology and several other apoptotic assays.
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tation and other apoptotic assays, were detected in normal
mucosa, fibroblasts, epithelial and endothelial cells. While
cancer cells underwent apoptosis after relatively brief treat-
ments, normal cells remained refractory even to prolonged
incubations with irofulven at concentrations that exceeded
up to hundred-fold the levels sufficient for growth inhibition
and apoptosis in tumor cells (Fig. 5A,B and Fig. 6).
Although data for oxaliplatin are less extensive, this drug
also showed indications of preferential apoptosis in some
tumor cells over normal cells (Fig. 5C,D) [64,73]. A pro-
found apoptosis in tumor cells with marginal effect in normal
peripheral blood cells was recently observed also for the
protein-reactive helenalin [74].
4.2. Cytotoxic versus cytostatic effects of irofulven
Importantly, the resistance of normal cells to irofulven
could not be accounted for by differences in drug accu-
mulation or drug covalent binding to macromolecules
[56,57,76]. Drug-induced growth inhibition paralleled the
Fig. 5. Differential induction of apoptosis in tumor (A,C) and normal (B,D) cells by dual-action drugs. Cells were treated with various concentrations of
irofulven for 4 h followed by 20 h post-incubation in drug-free medium (A,B) or with oxaliplatin for 24 h (C,D) before determination of apoptotic DNA
fragmentation. Human tumor cell lines: LNCaP-Pro5 ( ); LNCaP (E); LNCaP-LN3 (.); LNCaP-C4-2 (z); PC-3 (x); Colo 320DM (n); CEM ( ) and A2780
(6). Human normal cell lines: PrEC (5); NCM 460 (D); WI 38 ( w ) RPTEC (q) and HUVEC (o). The composite data in the figure are from the
Refs. [57,64,73]. (Panels A and B reprinted from B.A. Woynarowska, et al., Differential cytotoxicity and induction of apoptosis in tumor and normal
cells by hydroxymethylacylfulvene (HMAF), Biochem. Pharmacol. 59 (2000) 1217–1226, 59 pp. Copyright 2000, with permission from Elsevier).
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uptake of [14C]irofulven, although normal cells were three-
to four-fold more tolerant to the accumulated drug [57]. In
both tumor and normal cells, approximately two-thirds of
the internalized irofulven was bound covalently to macro-
molecules [57]. Notably, normal cells, even while growth
inhibited, maintained their viability for long times and
showed indications of continuation of growth after several
days. In contrast, progressive apoptosis in tumor cells
resulted in a profound decrease in viability paralleled by
the net decrease of cell number below the initial values (Fig.
6) [57,76]. Thus, irofulven is cytotoxic and apoptotic in
tumor cells but only cytostatic in normal cells. The qual-
itatively different responses of the tumor and normal cells
demonstrate an inherently greater tolerance of normal cells
to molecular lesions induced by irofulven. The possible
connection between this tolerance and redox homeostasis is
discussed below.
The potent and differential pro-apoptotic properties of
irofulven in tumor but not in normal cells strongly suggests
its potential utility as an apoptosis-enhancing agent in com-
bination with other modalities. Indeed, the combination of
irofulven with g-radiation was at least additive with indica-
tions of supra-additivity in terms of apoptosis and survival of
human prostate tumor cells [76]. Most importantly, irofulven
did not sensitize normal cells to ionizing radiation [76].
4.3. Distortion of redox homeostasis in tumor cells
The pattern of apoptosis induction by irofulven is con-
sistent with the distortion of the redox balance of the cancer
cell (Table 1) [73,78,79]. Several findings implicate TRX, a
key redox-controlling factor, in irofulven-induced apoptosis.
The drug can bind covalently to purified TRX [56], adduct-
ing one of its sulfhydryl groups [79]. In cancer cells,
irofulven causes an early and transient up-regulation of
TRX, which is detected at both mRNA and protein levels.
Consistently, TRX-dependent redox-sensing transcription
factors, nuclear factor nB (NF-nB) and activator protein 1
(AP-1) are also activated (Table 1). Irofulven treatment
results also in the early and profound translocation of pro-
apoptotic Bax to mitochondria, dissipation of mitochondrial
membrane potential, the release of cytochrome c, and
activation of a caspase cascade [78]. At later times, there
is a profound depletion in TRX protein levels (below the
basal level), accompanied by massive pro-oxidative changes
in cellular proteins, manifested as the increase in protein
carbonyls and decrease in protein sulfhydryls (Table 1, Ref.
[79]). The observed pattern suggests that irofulven induces a
rapid and possibly self-amplifying cascade of pro-oxidative
changes in cancer cells. Whereas further studies are needed
for better understanding of these effects, the profound and
irreversible collapse of the redox homeostasis supports the
notion that drug-induced protein damage may contribute to
apoptosis induction in cancer cells.
4.4. Redox-related responses in normal cells
Normal cells, in general, are believed to be better
protected from pro-oxidative insults than tumor cells
[18,80]. The greater capacity of normal cells to maintain
reducing conditions could explain their relative insensitivity
to drugs such as irofulven and oxaliplatin. For instance,
irofulven-resistant normal cells have markedly higher basal
TRX levels than irofulven-sensitive tumor cells (Table 1).
While irofulven also causes a transient stimulation of TRX
expression in normal cells, the initial TRX levels are soon
restored, and, in contrast to tumor cells, no TRX depletion is
observed (Table 1). Hence, irofulven-treated normal cells do
initiate redox-related responses, but their overall redox
homeostasis remains stable, even after prolonged times.
This pattern is consistent with the observed cytostatic effects
Fig. 6. Irofulven is cytotoxic for tumor but cytostatic for normal cells.
Tumor cells (prostate cancer LNCaP-Pro5) and normal cells (normal colon
mucosa NCM-460) were incubated with irofulven for various times as
indicated. Data for three endpoints are shown: cell growth inhibition (Panel
A), cell viability (by trypan blue exclusion, Panel B) and quantitative
apoptotic DNA fragmentation (Panel C). Note that normal cells were
treated with the 50-fold higher concentration of irofulven than cancer cells
(5 and 0.1 AM, respectively). Although normal cells are growth inhibited,
they remain viable and do not undergo apoptotic DNA fragmentation. Data
are the examples taken from Refs. [57,76].
Table 1
Differential redox-related responses to irofulven in tumor and normal cellsa
Cell line Tumorb Normalb
TRX protein basal level + + ++
TRX upregulation (mRNA and protein) ++ (transient) +++ (transient)
TRX protein depletion yes no
NF-nB binding activation + + + F (transient)
AP-1 binding activation + + + N.D.c
Increase in protein carbonyls + + + F
Decrease in protein sulfhydryls + + + 
Transcriptional responses + + + + ++
a Based on Refs. [73,78,79] and Liang et al., in preparation.
b Results obtained using prostate tumor LNCaP-Pro5 cells and normal
colon mucosa NCM-460 cells.
c N.D., not determined.
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of irofulven in normal cells, as opposed to cytotoxic effects
seen in cancer cells (c.f., Fig. 6). These findings warrant
further investigations to clarify the significance of TRX and
other redox-buffering elements in apoptosis by dual action
drugs, in particular in a broader range of cell lines with
varying basal TRX levels.
4.5. Bypass of apoptosis-inhibiting mechanisms by dual-
action drugs
Several studies showed that dual-action drugs may
remain pro-apoptotic under various pharmacologically
unfavorable conditions. Irofulven and oxaliplatin seem to
induce apoptosis in cancer cells regardless of their p53
status [57]. Pro-apoptotic effects of irofulven are largely
bcl-2-independent, as found in a system with forced bcl-2
overexpression [81]. Finally, irofulven apoptosis is appa-
rently not mediated by caspase-3, a generally important
apoptosis executioner. Consequently, irofulven retains its
full pro-apoptotic activity in caspase-3 deficient cells [77].
Hence, differences in the levels of pro- and anti-apoptotic
factors, which may, in principle, affect cellular responses
to various drugs, should be less critical for agents that
target the apoptotic process at multiple, nonoverlapping
points.
5. Concluding remarks
Both DNA damage and protein damage can, in principle,
promote apoptosis. While DNA damage initiates death
signaling, protein damage is known to distort the cell redox
homeostasis, which facilitates apoptosis execution. The
reviewed findings with novel anticancer drugs that react
with both DNA and proteins suggest that both reactivities
may indeed contribute to their pro-apoptotic properties. This
notion challenges the common belief that binding of such
drugs to cellular proteins is merely a detoxification event.
Clearly, further studies are needed to better understand
whether and when DNA damage alone, or in conjunction
with protein damage, determines the fate of cancer cells
treated with dual-action anticancer drugs.
Importantly, the reviewed investigations provide a proof
of principle that dual-action drugs can target apoptosis in
tumor cells, but spare normal cells. The qualitatively differ-
ent responses and profoundly greater tolerance of normal
cells to molecular lesions that promote apoptosis in tumor
cells point to fundamental differences that can be therapeuti-
cally exploited. In that context, it could be important that
drugs, such as irofulven, affect multiple cellular molecules.
Although damage to some specific targets might be partic-
ularly lethal, all the DNA- and protein-lesions may well act
in concert (Fig. 2). Hence, DNA- and protein-damaging
drugs can be perceived as agents targeting a process, rather
than a specific single biological entity, or one specific
pathway.
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